<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

3 min read

Acandis Inc: Targeting the US Market for Neurointervention

By Anne Staylor on 8/23/22 9:00 AM

Georg Schauer, PhD, President of Acandis Inc., discusses the Company, its novel devices and targeting the US market for neurointervention in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th annual meeting held in Toronto, Canada July 25-26, 2022

To find out more about how Acandis plans to differentiate itself and compete in the US market, click on the following video recorded live at SNIS 2022. (11:30 min). A link to download the complete transcript of the interview is also provided below. 

Continue Reading
3 min read

A Mixed Bag of Ups & Downs: Q122 CAS Ortho Recap

By Shelly Caruso on 8/19/22 9:30 AM

Q122 proved to be a mixed-bag of ups and downs with supply chain issues and Covid surges having varying impacts on market leaders’ performance amidst a strong wave of enabling tech product launches.

The Q122 WW CAS Ortho Market was down according to SmartTRAK Financial Dashboard. Stryker* remained the market leader, followed by Zimmer Biomet* and Smith & Nephew*. For detailed Q122 revenues and shares by company in the US, EU and ROW, see the SmartTRAK CAS Ortho Financial Dashboard.

Among the many topics covered in detail in our comprehensive Q122 CAS Ortho Market Recap* are:

Continue Reading
4 min read

BiologicsMD: Targeted Treatments for Bone Disorders and Hair Loss

By Freddy Buntoum on 8/16/22 9:47 AM

Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.

In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.

To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.

Continue Reading
2 min read

A Solid Recovery: Q122 Spine Market Recap

By Courtney Sheedy on 8/11/22 9:37 AM

Q122’s year-over-year growth in the WW Spine market shows normalized, nominal growth for this quarter, which should continue to improve over the course of the remaining year.

The US Spine Hardware market saw double-digit growth versus Q121, showing solid recovery gains from the same period prior year, which seemed to be riddled with ongoing volatility. Segment over segment within the spine market, we’re back to seeing growth in the areas that had been predicable growth segments prior to COVID-19. Although healthcare as a whole continues to rebuild, and staffing remains a challenge, many regions didn’t experience as negative an impact on the Spine market for Q122 as was predicted by many.

Among the many topics covered in detail in our comprehensive Q122 Spine Market Recap* are:

Continue Reading
3 min read

R92 Medical: Reimagining the Road to Stroke Interventions

By Anne Staylor on 8/9/22 9:30 AM

Adam Hattan, VP of Marketing for Route 92 Medical, discusses the Company, its novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at SNIS 2022.

Amid a growing number of me-too devices, one company that is differentiating itself in the market for stroke thrombectomy is Route 92 Medical (R92). Adam Hattan, R92’s vice president of marketing, discusses R92’s novel system for mechanical thrombectomy and competing in the market for stroke interventions in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) 19th Annual Meeting held in Toronto, Canada July 25-29, 2022.

To find out more about R92, its Monopoint operating platform and the Company’s strategies for growth, click on the following video recorded live at SNIS 2022.  (10:13 min). A link to download a transcript of the interview is also provided below.

Continue Reading
2 min read

New Spine Enabling Technologies: Q122 CAS Spine Market Recap

By Shelly Caruso on 8/5/22 12:15 PM

Although revenues still show signs of COVID-19 impact, robotic procedures and implant pull-through accelerate, and companies continue roll out new spine enabling technology and strategize how to maximize the remainder of 2022.

The Q122 WW CAS Spine Market was up year-over-year according to SmartTRAK Financial DashboardMedtronic* (MDT) remained the market leader with 59.5% share, followed by Globus* (GMED) and other enabling tech competitors, including Stryker* (SYK) and Brainlab*

Among the many topics covered in detail in our comprehensive Q122 CAS Spine Market Recap* are:

Continue Reading
2 min read

The Future of Biosensors and Smart Dressings in Wound Care Diagnostics

By Kris Flinn on 8/2/22 9:30 AM

Could biosensors and smart dressings be the final frontier in wound diagnostics? SmartTRAK explores the current progress of this market and how it could develop.

It has been 15 years since the World Union of Wound Healing Societies’ Initiative published a consensus document entitled “Diagnostics and Wounds.” Since then, the clinical practice around assessing and diagnosing wounds has not evolved at the same rate as that of treatments. At the same time, the need for improved wound diagnostics has never been greater given burgeoning chronic wound numbers and the continued shift of wound care services to the outpatient setting.

Could the next area of development be that of biosensors and smart dressings? SmartTRAK believes there is increasing evidence that this could be the case. In this article, we explore the developments that are taking place, how the identification of infection biomarkers may be lucrative and ways the market may change in the coming years.

Among the many topics discussed in this article are:

Topics: Wound Care
Continue Reading
2 min read

Healthy Growth w/ Mixed Results: Q122 Trauma Market Recap

By Natasha Weeks on 7/28/22 9:30 AM

Despite mixed results from Trauma players, the segment experienced healthy growth as mergers and acquisitions were plentiful and regulatory clearances show promise of future new product introductions.

Continue Reading
6 min read

Diagnostic and Digital Devices on Display: WOCNext 2022

By Gary Delhougne on 7/25/22 10:21 AM

Emerging from the COVID-19 era, wound care innovation is driven by small players, especially in the digital and diagnostic spaces

In June, wound, ostomy and continence-focused nurses, and supporting industry gathered in Fort Worth, TX for the hybrid WOCNext 2022 conference. In-person attendance was below expectations, but healthy booth time allowed for product discussions with exhibitors.

SmartTRAK observed that product innovation at WOCNext came from smaller companies and those focused on digital and diagnostic solutions not large manufacturers like Smith+Nephew*, 3M* or Mölnlycke*SmartTRAK learned that the large manufacturers are not launching new products for multiple reasons, including supply chain limitations, access to raw materials and the confidence to be able to supply enough products to serve the market.

SmartTRAK is closely watching advances and innovation in the digital and diagnostic space in wound care. Specifically, SmartTRAK Analyst Kris Flinn recently published an article, "The Future of Biosensors and Smart Dressings in Wound Care Diagnostics", available here, highlighting developments in diagnostic biosensors in smart dressings. Additionally, in an early 2022 interview with reimbursement expert Kathleen Schaum, we learned about reimbursement trends that support the development and use of these products. 

Outlined below are several wound diagnostic and digital products prominently highlighted at WOCN.

Topics: Wound Care
Continue Reading
2 min read

Trends in Neurovascular Innovation 2022

By Shelly Caruso on 7/21/22 9:30 AM

Improved aspiration systems, large-bore catheters, balloon-guide catheters and radial access top the list of neurovascular device trends that will continue in 2022.

In the market for mechanical thrombectomy devices, the pace of innovation shows no signs of slowing down in 2022. Manufacturers are designing neurointerventional devices with an eye toward improving first-pass effect, recanalization rates and reducing procedure times to ultimately improve patient outcomes In this article, SmartTRAK highlights recent trends in neurovascular technologies, including variable pressure aspiration systems, large-bore catheters (LBCs), balloon-guide catheters (BGCs) and radial access, as key areas of innovation moving into 2022.

Along with the recent trends in neurovascular technologies, the following topics are covered in detail in this article, which is available for download here:

  • Outgrowing Standard Aspiration Systems
  • Continued Trend Toward Large-Bore Catheters for Access and Aspiration
  • New Designs and Applications for Balloon-Guide Catheters
  • Increasing Competition in Radial Access
Continue Reading

    Follow Us on Social Media

    Recent Articles